MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patients
Ultragenyx's AAV8 vector gene therapy, DTX401, is advancing through clinical trials as potentially the first ever therapy to treat Glycogen Storage Disease Type 1a (GSD-1a). NEWTON, Mass., Sept. 28, 2023 /PRNewswire/ -- [...]
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)
Less than half of Graves' Disease patients achieve remission with anti-thyroid drugs, and nearly half of those that do will relapse. NEWTON, Mass., Aug. 16, 2023 /PRNewswire/ - Graves' Disease (GD) is [...]
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)
Apellis's anti-C3 Syfovre (pegcetacoplan intravitreal injection) and Astellas' anti-C5 Izervay (avacincaptad pegol intravitreal injection) were both recently FDA-approved to treat Geographic Atrophy (GA), but physicians are eager for more treatment [...]
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)
Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ -- IgA nephropathy (IgAN) is [...]
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patients
Ultragenyx's AAV8 vector gene therapy, DTX401, is advancing through clinical trials as potentially the first ever therapy to treat Glycogen Storage Disease Type 1a (GSD-1a). NEWTON, Mass., Sept. 28, 2023 /PRNewswire/ -- [...]
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)
Less than half of Graves' Disease patients achieve remission with anti-thyroid drugs, and nearly half of those that do will relapse. NEWTON, Mass., Aug. 16, 2023 /PRNewswire/ - Graves' Disease (GD) is [...]
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)
Apellis's anti-C3 Syfovre (pegcetacoplan intravitreal injection) and Astellas' anti-C5 Izervay (avacincaptad pegol intravitreal injection) were both recently FDA-approved to treat Geographic Atrophy (GA), but physicians are eager for more treatment [...]
Filspari and Tarpeyo launches off to a great start in IgAN (MARKETVUE® REPORT)
Surveyed nephrologists by REACH Market Research report that Filspari and Tarpeyo are already being prescribed to as many as 1 in 5 IgAN patients. NEWTON, Mass., July 27, 2023 /PRNewswire/ -- IgA nephropathy (IgAN) is [...]